Epidermal growth factor receptor inhibitor-related folliculitis [1]

Dermatitis

Volumn 18, Issue 3, 2007, Pages 178-179

  Tangri, Navdeep ^a   Al Hammadi, Anwar ^a   Gerstein, William ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOYL PEROXIDE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; MINOCYCLINE; RETINOIC ACID;

AGED; ANAMNESIS; CANCER STAGING; CASE REPORT; DRUG EFFICACY; DRUG TOLERABILITY; FOLLICULITIS; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SKIN BIOPSY;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; DIAGNOSIS, DIFFERENTIAL; DRUG ERUPTIONS; FACE; FOLLICULITIS; HUMANS; LUNG NEOPLASMS; MALE; NECK; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 35348906053     PISSN: 17103568     EISSN: None     Source Type: Journal    
DOI: 10.2310/6620.2007.06056     Document Type: Letter

References (3)

1. Bezjak A, Tu D, Seymour L, et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2006;24:3831-7.
2. Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005;6:491-500.
3. Perez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology 2003;17 Suppl 12: 23-8.